SOLASCURE Ltd (SolasCure), a biotechnology company developing a novel treatment to transform chronic wound healing, today announced the initiation of a new Phase II clinical trial, CLEANVLU2.
Does hormone-modulating therapy for breast cancer treatment affect risk for Alzheimer disease and related dementias?
The association between hormone-modulating therapy (HMT) for breast cancer treatment and the risk of developing Alzheimer’s disease and related dementias.